261 related articles for article (PubMed ID: 11400948)
1. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.
Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WJ; Weisdorf DF
Biol Blood Marrow Transplant; 2001; 7(5):265-73. PubMed ID: 11400948
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide for treatment of patients with chronic graft-versus-host disease.
Koc S; Leisenring W; Flowers ME; Anasetti C; Deeg HJ; Nash RA; Sanders JE; Witherspoon RP; Appelbaum FR; Storb R; Martin PJ
Blood; 2000 Dec; 96(12):3995-6. PubMed ID: 11090092
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
Kumar S; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Harmsen WS; Litzow MR
Bone Marrow Transplant; 2001 Jun; 27(11):1133-40. PubMed ID: 11551023
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide as salvage therapy for chronic graft-versus-host disease.
Parker PM; Chao N; Nademanee A; O'Donnell MR; Schmidt GM; Snyder DS; Stein AS; Smith EP; Molina A; Stepan DE; Kashyap A; Planas I; Spielberger R; Somlo G; Margolin K; Zwingenberger K; Wilsman K; Negrin RS; Long GD; Niland JC; Blume KG; Forman SJ
Blood; 1995 Nov; 86(9):3604-9. PubMed ID: 7579470
[TBL] [Abstract][Full Text] [Related]
5. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.
Koc S; Leisenring W; Flowers ME; Anasetti C; Deeg HJ; Nash RA; Sanders JE; Witherspoon RP; Storb R; Appelbaum FR; Martin PJ
Blood; 2002 Jul; 100(1):48-51. PubMed ID: 12070007
[TBL] [Abstract][Full Text] [Related]
6. Chronic graft-versus-host disease: a prospective cohort study.
Arora M; Burns LJ; Davies SM; Macmillan ML; Defor TE; Miller WJ; Weisdorf DJ
Biol Blood Marrow Transplant; 2003 Jan; 9(1):38-45. PubMed ID: 12533740
[TBL] [Abstract][Full Text] [Related]
7. The effect of budesonide mouthwash on oral chronic graft versus host disease.
Sari I; Altuntas F; Kocyigit I; Sisman Y; Eser B; Unal A; Fen T; Ferahbas A; Ozturk A; Unal A; Cetin M
Am J Hematol; 2007 May; 82(5):349-56. PubMed ID: 17109390
[TBL] [Abstract][Full Text] [Related]
8. De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival.
Wagner JL; Seidel K; Boeckh M; Storb R
Biol Blood Marrow Transplant; 2000; 6(6):633-9. PubMed ID: 11128814
[TBL] [Abstract][Full Text] [Related]
9. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.
Chao NJ; Snyder DS; Jain M; Wong RM; Niland JC; Negrin RS; Long GD; Hu WW; Stockerl-Goldstein KE; Johnston LJ; Amylon MD; Tierney DK; O'Donnell MR; Nademanee AP; Parker P; Stein A; Molina A; Fung H; Kashyap A; Kohler S; Spielberger R; Krishnan A; Rodriguez R; Forman SJ; Bluzme KG
Biol Blood Marrow Transplant; 2000; 6(3):254-61. PubMed ID: 10871150
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation.
Busca A; Saroglia EM; Lanino E; Manfredini L; Uderzo C; Nicolini B; Messina C; Rabusin M; Miniero R
Bone Marrow Transplant; 2000 May; 25(10):1067-71. PubMed ID: 10828867
[TBL] [Abstract][Full Text] [Related]
11. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.
Sullivan KM; Witherspoon RP; Storb R; Deeg HJ; Dahlberg S; Sanders JE; Appelbaum FR; Doney KC; Weiden P; Anasetti C
Blood; 1988 Aug; 72(2):555-61. PubMed ID: 3042042
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease.
Cragg L; Blazar BR; Defor T; Kolatker N; Miller W; Kersey J; Ramsay M; McGlave P; Filipovich A; Weisdorf D
Biol Blood Marrow Transplant; 2000; 6(4A):441-7. PubMed ID: 10975513
[TBL] [Abstract][Full Text] [Related]
14. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A;
Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide for the treatment of chronic graft-versus-host disease.
Vogelsang GB; Farmer ER; Hess AD; Altamonte V; Beschorner WE; Jabs DA; Corio RL; Levin LS; Colvin OM; Wingard JR
N Engl J Med; 1992 Apr; 326(16):1055-8. PubMed ID: 1549151
[TBL] [Abstract][Full Text] [Related]
16. Therapy of chronic graft-v-host disease in a rat model.
Vogelsang GB; Hess AD; Friedman KJ; Santos GW
Blood; 1989 Jul; 74(1):507-11. PubMed ID: 2752128
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
[TBL] [Abstract][Full Text] [Related]
18. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.
Sullivan KM; Witherspoon RP; Storb R; Weiden P; Flournoy N; Dahlberg S; Deeg HJ; Sanders JE; Doney KC; Appelbaum FR
Blood; 1988 Aug; 72(2):546-54. PubMed ID: 3042041
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival.
Ross M; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM; Smith EP; Snyder DS; Stein AS; Wong RM; Forman SJ; Blume KG; Chao NJ
Biol Blood Marrow Transplant; 1999; 5(5):285-91. PubMed ID: 10534058
[TBL] [Abstract][Full Text] [Related]
20. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
